Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Molecular Partners ( (MOLN) ).
On January 11, 2026, Molecular Partners reported broad clinical and pipeline progress ahead of its presentation at the 44th J.P. Morgan Healthcare Conference, underscoring its push to establish leadership in targeted radiotherapeutics and novel immune-oncology modalities. The company has initiated a Phase 1/2a U.S. trial of its lead Radio-DARPin MP0712 for small cell lung cancer and other neuroendocrine tumors, with first patient dosing expected in the first quarter of 2026 and initial data due later in the year, supported by encouraging compassionate-use imaging data to be shown at the Theranostics World Congress 2026. Its second radiotherapy program, MP0726 for mesothelin-positive cancers including ovarian cancer, continues to advance alongside four additional radio-oncology projects, guided by a new scientific advisory board of nuclear medicine experts. Beyond radiotherapy, a Phase 2 investigator-initiated trial of tumor-localized CD40 agonist MP0317 in cholangiocarcinoma has begun treating patients in early 2026, and the Phase 1/2a study of tetra-specific T cell engager MP0533 in relapsed/refractory AML is ongoing with densified dosing showing tolerability and early antitumor signals as of data presented in December 2025. Molecular Partners also plans to nominate its first Switch-DARPin candidate, a logic-gated T cell engager for solid tumors, in the first half of 2026. Financially, the company reported unaudited cash and cash equivalents of CHF 93.1 million as of December 31, 2025, which management believes will fund operations into 2028, providing a multi-year runway to execute its 2026 clinical and strategic milestones, with full 2025 results scheduled for March 12, 2026.
The most recent analyst rating on (MOLN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.
Spark’s Take on MOLN Stock
According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.
The overall stock score of 51 reflects significant financial challenges, including declining revenue and negative profitability margins, which are partially offset by positive technical indicators suggesting short-term bullish momentum. The negative P/E ratio and lack of dividend yield further weigh on the valuation.
To see Spark’s full report on MOLN stock, click here.
More about Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company based in Zurich-Schlieren, Switzerland, with operations in Concord, Massachusetts, focused on developing DARPin (Designed Ankyrin Repeat Protein) therapeutics, a novel class of engineered protein drugs. Its pipeline spans radio-ligand therapies (Radio-DARPins) for solid tumors, tumor-localized immuno-oncology agents, and multi-specific T cell engagers, targeting high-unmet-need indications such as small cell lung cancer, ovarian cancer, cholangiocarcinoma, and acute myeloid leukemia. The company is listed on the SIX Swiss Exchange and Nasdaq under the ticker MOLN and collaborates with partners such as Orano Med to advance targeted alpha radiotherapies.
Average Trading Volume: 6,099
Technical Sentiment Signal: Hold
Current Market Cap: $166.7M
See more data about MOLN stock on TipRanks’ Stock Analysis page.